Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab and ADG126 in MSS Advanced/Metastatic Colorectal Cancer
NCT07363408Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of muzastotug and ivonescimab in colorectal cancer (CRC) (3 arms), sponsored by City of Hope. Primary endpoint: Incidence of dose limiting toxicities at 6 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
muzastotugivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07363408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363408.